DE60035196T2 - Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden - Google Patents

Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden Download PDF

Info

Publication number
DE60035196T2
DE60035196T2 DE60035196T DE60035196T DE60035196T2 DE 60035196 T2 DE60035196 T2 DE 60035196T2 DE 60035196 T DE60035196 T DE 60035196T DE 60035196 T DE60035196 T DE 60035196T DE 60035196 T2 DE60035196 T2 DE 60035196T2
Authority
DE
Germany
Prior art keywords
profile data
data set
calibrated
group
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60035196T
Other languages
German (de)
English (en)
Other versions
DE60035196D1 (de
Inventor
Victor Loveland TRYON
Michael P. Boulder BEVILACQUA
Danute M. Longmont BANKAITIS-DAVIS
John Conifer CHERONIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Source Precision Medicine Inc
Original Assignee
Source Precision Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26839213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60035196(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Source Precision Medicine Inc filed Critical Source Precision Medicine Inc
Application granted granted Critical
Publication of DE60035196D1 publication Critical patent/DE60035196D1/de
Publication of DE60035196T2 publication Critical patent/DE60035196T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60035196T 1999-06-28 2000-06-28 Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden Revoked DE60035196T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14154299P 1999-06-28 1999-06-28
US141542P 1999-06-28
US19552200P 2000-04-07 2000-04-07
US195522P 2000-04-07
PCT/US2000/017846 WO2001025473A1 (en) 1999-06-28 2000-06-28 Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles

Publications (2)

Publication Number Publication Date
DE60035196D1 DE60035196D1 (de) 2007-07-26
DE60035196T2 true DE60035196T2 (de) 2008-02-21

Family

ID=26839213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035196T Revoked DE60035196T2 (de) 1999-06-28 2000-06-28 Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden

Country Status (13)

Country Link
EP (1) EP1198585B1 (https=)
JP (1) JP2004528526A (https=)
KR (1) KR20020079364A (https=)
AT (1) ATE364721T1 (https=)
AU (1) AU784233B2 (https=)
CA (1) CA2378008A1 (https=)
CY (1) CY1107733T1 (https=)
DE (1) DE60035196T2 (https=)
DK (1) DK1198585T3 (https=)
ES (1) ES2290046T3 (https=)
IL (2) IL147349A0 (https=)
PT (1) PT1198585E (https=)
WO (1) WO2001025473A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
AUPR480901A0 (en) * 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
EP1392871A4 (en) * 2001-05-22 2006-04-19 Gene Logic Inc MODELING MOLECULAR TOXICITY
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2277991A1 (en) * 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
JP4632788B2 (ja) 2002-09-20 2011-02-16 ニュー・イングランド・バイオラブズ・インコーポレイティッド 核酸のヘリカーゼ依存性増幅
AU2002952696A0 (en) * 2002-11-14 2002-11-28 Genomics Research Partners Pty Ltd Status determination
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
WO2004057034A1 (en) * 2002-12-19 2004-07-08 Source Precision Medicine, Inc. Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
AU2003901196A0 (en) * 2003-03-17 2003-04-03 Commonwealth Scientific And Industrial Research Organisation Analysis method
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
JPWO2005087924A1 (ja) * 2004-02-18 2008-01-31 株式会社三重ティーエルオー Ｄｎａチップ並びに疾患関連遺伝子の抽出方法
EP2062981B1 (en) 2005-06-16 2013-09-25 Life Technologies Corporation Gene expression profiling for identification and monitoring of multiple sclerosis
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
AU2007254206A1 (en) * 2006-05-16 2007-11-29 Source Mdx Assessment of effect of an agent on a human biological condition using rodent gene expression panels
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2315858A2 (en) 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
NZ593854A (en) 2009-01-06 2013-02-22 Source Prec Medicine Inc D B A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
US9074248B1 (en) 2012-12-18 2015-07-07 Qiagen Gmbh Primers for helicase dependent amplification and their methods of use
CN103525926B (zh) * 2013-10-08 2016-03-23 浙江大学 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5922184A (en) * 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
EP0960214A4 (en) * 1996-12-06 2004-08-04 Urocor Inc Diagnosis of disease status on HAnd from mRNA profiles
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
WO1999011822A1 (en) * 1997-09-03 1999-03-11 Gene Logic Inc. Method for predicting prognosis and treatment response for genetically based abnormalities
US6461817B1 (en) * 1997-09-12 2002-10-08 The Public Health Research Institute Of The City Of New York Non-competitive co-amplification methods
EP1027456B1 (en) * 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs

Also Published As

Publication number Publication date
EP1198585B1 (en) 2007-06-13
AU784233B2 (en) 2006-02-23
ATE364721T1 (de) 2007-07-15
AU5898500A (en) 2001-05-10
DK1198585T3 (da) 2007-10-15
JP2004528526A (ja) 2004-09-16
KR20020079364A (ko) 2002-10-19
CY1107733T1 (el) 2013-04-18
PT1198585E (pt) 2007-09-20
IL147349A0 (en) 2002-08-14
EP1198585A1 (en) 2002-04-24
WO2001025473A9 (en) 2002-08-08
IL147349A (en) 2011-12-29
DE60035196D1 (de) 2007-07-26
CA2378008A1 (en) 2001-04-12
WO2001025473A1 (en) 2001-04-12
ES2290046T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
DE60035196T2 (de) Verfahren zum Charakterisieren von biologischen Bedingungen, die kalibrierte Genexpressionsprofile verwenden
Bakken et al. Comparative cellular analysis of motor cortex in human, marmoset and mouse
Broeckling et al. Current practices in LC-MS untargeted metabolomics: a scoping review on the use of pooled quality control samples
US6692916B2 (en) Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
Boedigheimer et al. Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
Agus et al. The caudate nucleus undergoes dramatic and unique transcriptional changes in human prodromal Huntington’s disease brain
EP1348032A2 (de) Verfahren zur bestimmung der homeostase der haut
DE112019005389T5 (de) Techniken zum erkennen von optimalen kombinationen von arzneimitteln
Songthawornpong et al. Is there a correlation between the number of brain cells and IQ?
EP1579008A1 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
AU2003303238A2 (en) Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles
Kirwan Metabolomics for the practising vet
WO2017202713A1 (de) Verfahren und system zur dokumentation eines diagnostischen tests
Fernandez et al. Network analysis of inflammatory bowel disease research: towards the interactome
DE10328033A1 (de) Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose
Spriggs et al. Comparison of selected cytomorphological features of canine pemphigus foliaceus and superficial pyoderma
EP1658380A2 (de) Verfahren zur bestimmung von haarzyklus-markern
Bahl et al. NEUROeSTIMator: Using Deep Learning to Quantify Neuronal Activation from Single-Cell and Spatial Transcriptomic Data
BE1030423B1 (de) Anwendung von Biomarkern zu Diagnose und Behandlung von pulmonaler Hypertonie (PH)
DE102023123433A1 (de) Arzneimittelscreening unter Verwendung eines an Proben von Probanden erzeugten Responsom-Profils
De Abrew et al. Exploration of oxidative stress-mediated genetic toxicology modes of action using a pathway analysis, Connectivity Mapping, and transcriptional benchmark dosing-based framework
Liu et al. standR: a Bioconductor package for analysing transcriptomic Nanostring GeoMx DSP data
Westerberg et al. The topography of relapse in clinical samples
Kleinhans et al. Microsatellite genotypes of the South African Cape vulture, Gyps coprotheres
Matsuyama Cytogenetic studies of marijuana

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation